Geron's stock price was cut in half on 10 September when the company said it would abandon development of its lead drug candidate in the treatment of solid tumours, because imetelstat failed in a Phase II clinical trial to improve progression-free survival (PFS) in patients with metastatic HER2-negative breast cancer.
Geron's stock price was cut in half on 10 September when the company said it would abandon development of its lead drug candidate in the treatment of solid tumours, because imetelstat failed in a Phase II clinical trial to improve progression-free survival (PFS) in patients with metastatic HER2-negative breast cancer.
The announcement comes less than a year after Geron returned a $25 million loan for its stem cell programme to the state of California so it could focus on its oncology pipeline (
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
